Form 4 Royalty Pharma Plc For: 30 September By Investing.com
This article announces the filing of a Form 4 for Royalty Pharma Plc for the period ending September 30. It includes the publication date and time, the company's stock symbol (RPRX), and a brief mention of its current performance (-1.14%). The content primarily consists of financial market data and popular news headlines from Investing.com.
Form 4 Royalty Pharma Plc For: 30 September By Investing.com
This article reports on the filing of Form 4 by Royalty Pharma Plc for the period ending September 30. It includes a brief mention of the company's stock symbol RPRX and its performance. The content is primarily a placeholder for the Form 4 details, presented within the Investing.com financial news framework.
A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX).
Royalty Pharma plc director Bonnie L. Bassler acquired 642 Class A Ordinary Shares on September 30, 2026. This acquisition was made under the 2020 Independent Director Equity Incentive Plan as a quarterly retainer payment of $37,500. Following this transaction, her direct holdings in the company totaled 79,823 shares.
4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist.
Royalty Pharma EVP Marshall Urist sold 4,126 Class A Ordinary Shares at $57.88 per share on September 28, 2026, under a prearranged Rule 10b5-1 trading plan. After the transaction, Urist directly held 4,126 shares and indirectly held 19,020 shares through an IRA. The sale was reported in a Form 4 filing, which also detailed additional indirect holdings via limited partnership interests and Class E Ordinary Shares subject to vesting.
Form 4 Royalty Pharma Plc For: 30 September By Investing.com
This article reports on the filing of Form 4 by Royalty Pharma Plc for the period ending September 30. It's a brief announcement from Investing.com, providing basic financial news without additional details in the content. The report confirms the filing with the stock symbol RPRX mentioned.
Royalty Pharma EVP Marshall Urist sells $238,812 in shares
Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 4,126 Class A Ordinary Shares worth $238,812 on September 28, 2026, through a pre-arranged 10b5-1 trading plan. This transaction follows strong performance by Royalty Pharma shares and comes amidst the company reporting robust Q2 2026 financial results and a thriving biotech funding environment.
Operating cash flow per share of Royalty Pharma Plc Class A – HAN:RPD
This article provides financial data specifically focusing on the operating cash flow per share of Royalty Pharma Plc Class A (HAN:RPD) on the Hannover Stock Exchange. The content is primarily a data display with no additional textual analysis or details beyond the stock information. It appears to be a snapshot from a financial tracking platform.
Royalty Pharma officer proposes $239K share sale | RPRX SEC Filing - Form 144
Royalty Pharma plc (RPRX) officer Marshall Urist has proposed selling 4,126 Class A ordinary shares, valued at $238,812.88, through Merrill Lynch on September 28, 2026. These shares originated from an equity performance award granted on August 5, 2026. The filing also discloses four previous common-stock sales by Urist between May and July 2026, totaling over $2.4 million.
Royalty Pharma EVP Christopher Hite sells $5.85m in shares
Royalty Pharma's EVP Christopher Hite sold 100,000 Class A ordinary shares for approximately $5.85 million on September 22, 2026, executed under a pre-arranged trading plan. This insider sale occurs as Royalty Pharma shares have seen a 70% return over the past year, though InvestingPro analysis suggests the stock is currently overvalued. Hite retains significant indirect ownership and other interests in the company.
Form 4 Royalty Pharma Plc For: 25 September By Investing.com
This article from Investing.com announces the filing of a Form 4 for Royalty Pharma Plc on September 25. The content primarily consists of market data, news headlines, and various financial tool advertisements typical of a financial news platform.
A prearranged plan governed SCH Investment Partners’ sale of 100,000 Royalty Pharma (RPRX) shares.
SCH Investment Partners LLC, controlled by Royalty Pharma's EVP & Chairman, Partnering Christopher Hite, sold 100,000 Class A ordinary shares of Royalty Pharma (RPRX) on September 22, 2026. These sales, totaling approximately $5.85 million, were executed under a pre-arranged Rule 10b5-1 plan adopted on March 20, 2026. Following the transactions, Hite directly holds 23,200 shares, with family vehicles holding additional exchangeable interests.
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares
SCH Investment Partners LLC plans to sell 100,000 Class A Ordinary Shares of Royalty Pharma plc (RPRX) with an aggregate market value of approximately $5.8 million through Merrill Lynch, as detailed in a recent SEC Form 144 filing. This follows previous sales of 350,000 Class A Ordinary Shares by the same entity over the past three months under a Rule 10b5-1(c) selling plan. The shares for the new sale were acquired in a private transaction on May 13, 2024.
Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock Price, Quote, News & History
This page provides stock price information, quotes, news, and historical data for Royalty Pharma plc Class A Ordinary Shares (RPRX) on Nasdaq. It includes details on bid/ask prices, data disclaimers, and emphasizes that key data is currently unavailable. The content highlights the importance of bid-ask spread for liquidity and order execution.
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week High - What's Next?
Royalty Pharma (NASDAQ:RPRX) recently achieved a new 52-week high of $62.58, with analysts maintaining a "Buy" rating and an average target price of $60.86. Despite revenue missing estimates, the company surpassed EPS expectations in its latest quarterly results. Royalty Pharma also announced a quarterly dividend of $0.235 per share, though insiders have sold a significant amount of stock recently.
Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX
Headlands Technologies LLC has acquired a new stake in Royalty Pharma PLC, purchasing 90,729 shares valued at approximately $5.09 million during the second quarter. Other institutional investors have also increased their holdings in the biopharmaceutical company, which has reported quarterly EPS of $1.32, beating estimates, despite revenue falling short of consensus forecasts. Analysts generally maintain a positive outlook for Royalty Pharma, with an average price target of $60.86.
Odyssean LLC Acquires 21,401 Shares of Royalty Pharma PLC $RPRX
Odyssean LLC increased its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 65.3% in Q2 2026, acquiring an additional 21,401 shares, bringing its total holdings to 54,179 shares valued at $3.04 million. The biopharmaceutical company reported Q2 EPS of $1.32, surpassing estimates, though revenue of $674.14 million missed expectations. Analysts maintain a bullish outlook with an average price target of $60.86, and Royalty Pharma declared a quarterly dividend of $0.235, representing a 1.5% annualized yield.
RPRX | Royalty Pharma plc Class Financials - Revenue Breakdown
This article provides a detailed financial overview of Royalty Pharma plc (RPRX), focusing on its revenue breakdown and other key financial metrics. It includes sections on insider trading, institutional holdings, analyst ratings, and information about the company's business model as the largest buyer of biopharmaceutical royalties. The report highlights the absence of specific revenue breakdown by segment or geography, congressional trading data, corporate lobbying instances, and recent patent grants for RPRX.
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 11,002 Class A Ordinary Shares worth $645,551 on August 13, 2026, through a pre-arranged trading plan. The sales occurred as the stock traded near its 52-week high, with shares up 67% over the past year. Despite the sales, Coyne retains significant beneficial ownership through direct holdings and various indirect interests.
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock
Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma (RPRX), reported insider activity including the sale of 100,000 Class A Ordinary Shares by an associated entity, SCH Investment Partners LLC, at a weighted average price of $59.9725 per share. The sale was executed under a Rule 10b5-1 trading plan. Additionally, Hite made a charitable gift of 16,800 Class A Ordinary Shares to Lehigh University, impacting his direct and indirect holdings in the company.
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity
Christopher Hite, EVP and Chairman of Partnering at Royalty Pharma plc, sold 100,000 Class A Ordinary Shares for approximately $5.99 million under a 10b5-1 trading plan. Additionally, he donated 16,800 shares to Lehigh University. Following these transactions, Hite retains significant direct and indirect ownership in the company.
Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale
SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma (NASDAQ: RPRX) with an aggregate market value of $6,012,000. These shares were acquired in private transactions in 2024 and 2025 and represent a small fraction of Royalty Pharma's 445,277,344 outstanding shares. The planned sale is part of a pre-arranged selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c), and follows previous sales by SCH Investment Partners LLC in June 2026.
Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated
Pablo Legorreta has updated his beneficial ownership in Royalty Pharma (NASDAQ: RPRX) through an amended SEC filing, reporting a stake of 101.8 million Class A shares, representing 18.73% of the class. This includes shares issuable under an A&R Exchange Agreement, and the recalculation follows a change in the number of outstanding Class A shares. The filing also details recent equity transactions, including the acquisition of shares from performance awards and a gift of partnership interests.
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares
Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, sold 11,002 Class A Ordinary Shares totaling $645,551 on August 13, 2026, under a Rule 10b5-1 trading plan. The shares were sold in multiple transactions at prices ranging from $57.99 to $59.52. Despite this insider sale, Royalty Pharma recently reported strong Q2 2026 results with increased royalty receipts and a raised full-year outlook, leading BofA Securities to increase its price target.
Royalty Pharma (RPRX) CFO sells 11,002 shares in trading plan
Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 11,002 Class A Ordinary Shares of RPRX on August 13, 2026, through a Rule 10b5-1 plan. The sales were executed in two blocks at weighted average prices of $58.5864 and $59.1415, totaling approximately $646K. Following these transactions, Coyne retains significant indirect holdings, including shares in IRAs and exchangeable interests in limited partnerships.
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 11,002 Class A Ordinary Shares totaling $645,551 through a Rule 10b5-1 trading plan. The sales occurred on August 13, 2026, with shares trading near their 52-week high. Despite the sales, Coyne retains significant direct and indirect holdings in the company.
Royalty Pharma CFO Terrance P. Coyne Executes Class A Share Sales via 10b5-1 Plan
Royalty Pharma plc's CFO, Terrance P. Coyne, sold 11,002 Class A Ordinary Shares on August 13, 2026, through a pre-established 10b5-1 trading plan. The sales occurred in two tranches at weighted average prices of $58.5864 and $59.1415 per share. Following these transactions, Coyne retains significant direct and indirect holdings in the company.
RPRX (RPRX) investor files to sell 125,000 Class A shares on NASDAQ
A shareholder of Royalty Pharma plc (RPRX) has filed a Form 144 to sell 125,000 Class A ordinary shares on NASDAQ through J.P. Morgan Securities LLC, with an indicated aggregate market value of $7,223,750. The filing, dated August 12, 2026, notes the planned sale is related to a conversion of LP Interests on August 7, 2026. This potential sale represents a small fraction of the 445,277,344 Class A ordinary shares outstanding.
Royalty Pharma (RPRX) files to potentially sell 11.9M Class A shares
Royalty Pharma plc (RPRX) has filed a Form 144 notice indicating a proposed sale of up to 11,925,082 Class A ordinary shares through J.P. Morgan Securities LLC on NASDAQ. These shares were acquired through various means, including a significant block from a Conversion of LP Interests and multiple compensation grants from the issuer dating back to 2021. The filing provides detailed figures on the share blocks and the acquisition dates, clarifying the nature of the transaction.
Royalty Pharma (RPRX) CEO gets share award and gifts partnership interests
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma (RPRX), received an exempt award of 65,216 Class A Ordinary Shares as settlement for Equity Performance Awards, increasing his direct holdings to 1,307,820 shares. He also made a bona fide gift of 30,000 LP interests in RPI US Partners 2019, LP, representing 300,000 underlying Class A shares. The filing details his substantial direct and indirect holdings, including exchangeable Class B and Class E shares held through family entities and trusts.
Royalty Pharma (RPRX) EVP gets 8,252 shares, gifts LP interests
Royalty Pharma EVP Urist Marshall received 8,252 Class A Ordinary Shares as an exempt award and gifted 3,000 limited partnership interests, which are exchangeable into 30,000 Class A shares. Marshall also holds indirect Class A shares through an IRA and Class E Ordinary Shares exchangeable into over 1.3 million additional Class A shares. These transactions were reported via an SEC Form 4 filing.
Royalty Pharma (NASDAQ: RPRX) EVP gets 11,002-share Class A equity award
Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma (NASDAQ: RPRX), was awarded 11,002 Class A Ordinary Shares on August 5, 2026, as part of an exempt grant connected to the settlement of Equity Performance Awards. This transaction increased the indirect holdings through SCH Investment Partners LLC to 470,401 shares, while Hite also directly holds 40,000 Class A Ordinary Shares. Additionally, family vehicles controlled by Hite hold interests exchangeable into over 2 million more Class A Ordinary Shares.
Royalty Pharma plc (RPRX) CFO logs equity award and 18,500-share gift
Royalty Pharma plc CFO Terrance P. Coyne reported an acquisition of 11,002 Class A Ordinary Shares through an exempt settlement of Equity Performance Awards and an indirect bona fide gift of 18,500 Class E Ordinary Shares. Following the gift, Coyne indirectly holds 1,788,777 Class E shares, which are subject to vesting and convertible into Class A shares. Additionally, Coyne and related entities maintain significant holdings, including limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares.
Royalty Pharma Plc Class A Revenue Breakdown – HAM:RPD
This article provides a revenue breakdown for Royalty Pharma Plc Class A (HAM:RPD). It highlights that in the last year, the company generated 2.77 billion EUR, with the Biopharmaceutical Royalties segment being the top performer, contributing 2.02 billion EUR. The United States was identified as the greatest contributor by region, also accounting for 2.02 billion EUR.
Total equity of Royalty Pharma Plc Class A – HAM:RPD
This article displays the total equity of Royalty Pharma Plc Class A (HAM:RPD) on the Hamburg Stock Exchange. It provides a snapshot of the company's financials through TradingView, indicating that the market was closed with no trades at the time of viewing. The content confirms the article is about financial data for Royalty Pharma Plc Class A.
Royalty Pharma Plc Class A Revenue Breakdown – HAM:RPD
Royalty Pharma Plc Class A (HAM:RPD) generated €2.77 billion in revenue last year, primarily from its Biopharmaceutical Royalties segment, which accounted for €2.02 billion. The United States was the largest contributor to this revenue, also bringing in €2.02 billion. This data provides a breakdown of the company's top-performing segments and geographical contributions.
Royalty Pharma Plc Class A Revenue Breakdown – TRADEGATE:RPD
Royalty Pharma Plc Class A (RPD) generated €2.77 billion in revenue last year, with its Biopharmaceutical Royalties segment contributing the most at €2.02 billion. The United States was the largest regional contributor, also bringing in €2.02 billion. This data highlights the company's key revenue drivers and geographic focus.
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
Royalty Pharma has acquired a royalty interest in AstraZeneca's cliramitug from Neurimmune for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 TTR-fibril-depleting antibody for TTR amyloidosis with cardiomyopathy (ATTR-CM), a rapidly growing market. This investment targets a significant unmet medical need and supports Neurimmune's R&D pipeline.
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share
Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation in the sector, holding royalties on over 35 commercial products and 19 development-stage candidates. This dividend announcement reflects strong financial health and a commitment to shareholder value, though it also raises questions about reinvestment opportunities and future strategic plans.
Royalty Pharma dividend arrives Sept. 10 for Aug. 14 record-date holders
Royalty Pharma (Nasdaq: RPRX) has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share. This dividend will be paid on September 10, 2026, to shareholders who are on record as of August 14, 2026. Royalty Pharma is known as the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry.
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share
Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation in the sector. Its portfolio includes royalties from over 35 commercial products and 19 development-stage candidates.
Royalty Pharma declares $0.235 dividend for Q3 2026, payable September 10
Royalty Pharma plc has declared a dividend of $0.235 per Class A ordinary share for the third quarter of 2026. This dividend is scheduled to be paid on September 10, 2026, to shareholders recorded by August 14, 2026. The announcement highlights the company's consistent strategy of returning value to its shareholders, supported by its significant portfolio of biopharmaceutical royalties.
ETFs Investing in Royalty Pharma Plc Class A Stocks
This article lists various ETFs that include Royalty Pharma Plc Class A (RPD) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of RPD, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover a range of investment focuses, from diversified total market funds to sector-specific and ESG-focused options.
Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades
Royalty Pharma plc's EVP Christopher Hite sold 130,000 Class A Ordinary Shares on June 30, 2026, as part of a pre-arranged 10b5-1 trading plan. The shares were sold at weighted average prices between approximately $56 and $57. Hite now directly holds 40,000 shares, with an additional 461,953 shares held indirectly through SCH Investment Partners LLC.
[Form 4] Royalty Pharma plc Insider Trading Activity
Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares on July 1, 2026, at a weighted average price of $55.8802 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following the sale, Urist directly holds no Class A shares but maintains an indirect holding of 19,020 shares through an IRA.
Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M
Royalty Pharma plc insider Marshall Urist filed Form 144 notices for proposed sales of Common Stock, totaling approximately $1.95 million across three transactions in May and June 2026. The filing also disclosed an Equity Performance Award of 9,099 Class A Ordinary Shares granted on May 8, 2026, as part of the company's equity compensation program. While the sales don't explicitly link to the award, the various transactions relate to Urist's holdings.
[144] Royalty Pharma plc SEC Filing
This article reports a Form 144 SEC filing by Royalty Pharma plc (RPRX), indicating a proposed sale of 100,000 Class A Ordinary Shares with an aggregate market value of $5,709,000. These shares were acquired from the issuer in a private transaction on February 14, 2025. The filing, accepted by the SEC on July 1, 2026, also details the securities exchange as NASDAQ.
Royalty Pharma (RPRX) director gets equity grant in lieu of cash
Royalty Pharma (RPRX) director Bonnie L. Bassler received an equity grant of 689 Class A Ordinary Shares as compensation, valued at $37,500, in lieu of a quarterly cash retainer. The shares were issued under the company’s 2020 Independent Director Equity Incentive Plan, with each share valued at $54.3998. Following this transaction, Bassler directly holds 79,181 Class A Ordinary Shares, highlighting a non-cash compensation method rather than an open-market purchase or sale.
Enterprise value to revenue forward of Royalty Pharma Plc Class A – SWB:RPD
The article mentions the enterprise value to revenue forward for Royalty Pharma Plc Class A, traded on the Stuttgart Stock Exchange under the symbol RPD. It is a financial data point for the company in the Pharmaceuticals: Major industry within Health Technology. The content provided is minimal and appears to be a stub or a section of a larger financial information display, highlighting the period and value change.
Price to earnings forward of Royalty Pharma Plc Class A – SWB:RPD
This article provides access to the "Price to earnings forward" financial metric for Royalty Pharma Plc Class A (SWB:RPD) on TradingView. It indicates that the market for this stock was closed with no trades at the time of access. The primary content focuses on directing users to financial data for the company.
Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan
An entity linked to Christopher Hite, EVP and Chairman, Partnering at Royalty Pharma plc, sold 150,000 Class A Ordinary Shares in open-market transactions on June 23, 2026. These sales, executed at weighted average prices around $54, were pre-planned under a Rule 10b5-1 trading plan adopted in March 2026. Following these transactions, Hite and the associated entity still retain a substantial holding of Royalty Pharma shares.
